Johnson & Johnson has entered a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held company focused on developing drugs to treat hormonally-driven cancers, for $650 million upfront and as much as $350 million based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. The acquisition includes Aragon’s androgen receptor antagonist program. Its lead product candidate is a second-generation androgen receptor signalin...